# Asunaprevir

## Sunvepra 100mg

| 藥物代碼 | OSUN |
| :--- | :--- |
| 適應症 | Chronic hepatitis C: Treatment of chronic hepatitis C \(CHC\) in adult patients with hepatitis C virus \(HCV\) genotypes 1 or 4 and compensated liver disease, including cirrhosis. Must be administered as part of combination therapy with other anti-HCV agents. |
| 副作用 | &gt;10%:Central nervous system: Fatigue \(12% to 39%\), headache \(6% to 28%\), insomnia \(4% to 21%\), irritability \(16%\)Dermatologic: Pruritus \(6% to 25%\), skin rash \(5% to 18%\), alopecia \(3% to 16%\)Gastrointestinal: Nausea \(4% to 15%\)Hematologic & oncologic: Anemia \(19%\), neutropeniaHepatic: Increased serum AST \(2% to 13%\), increased serum ALT \(4% to 12%\)Neuromuscular & skeletal: Weakness \(23%\)Respiratory: Flu-like symptoms \(22%\)1% to 10%:Cardiovascular: Atrial fibrillation, hypertension, syncopeCentral nervous system: Amnesia, anxiety, depression, disturbance in attention, dizziness, emotional lability, malaise, pain, sleep disorder, vertigoDermatologic: Dermatitis, eczema, erythema, exfoliative dermatitis, maculopapular rash, psoriasis, seborrheic dermatitis, xerodermaEndocrine & metabolic: Weight lossGastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, dyspepsia, dysphagia, hemorrhoids, stomatitis, vomitingHematologic & oncologic: Eosinophilia, leukopenia, lymphocytopenia, thrombocytopeniaHepatic: Increased serum bilirubin \(1% to 10%\), hyperbilirubinemiaInfection: InfluenzaNeuromuscular & skeletal: Arthralgia, back pain, musculoskeletal chest pain, myalgiaOphthalmic: XerophthalmiaRespiratory: Cough, dyspnea, dyspnea on exertion, nasopharyngitis, oropharyngeal painMiscellaneous: Fever&lt;1% \(Limited to important or life-threatening\): Erythema multiforme |
| 禁忌 | Hypersensitivity to asunaprevir or any component of the formulation; moderate or severe hepatic impairment \(Child-Pugh class B or C, score 7 or greater\) and with decompensated hepatic disease; concurrent use with daclatasvir, peginterferon alfa, and ribavirin in women who are pregnant or may become pregnant and men whose female partners are pregnant, may be pregnant, or plan to become pregnant; concurrent use with drugs dependent on the cytochrome P450 2D6 \(CYP2D6\) for clearance and for which elevated plasma concentrations are associated with serious ventricular arrhythmias and sudden death; concurrent use with moderate or strong inducers and inhibitors of CYP3A or with strong inhibitors of organic anion transporting polypeptide \(OATP\) 1B1 or 2B1. The following drugs are included in the manufacturer labeling as being contraindicated: atazanavir, bosentan, carbamazepine, clarithromycin, cobicistat or cobicistat-containing regimens, cyclosporine, darunavir/ritonavir, dexamethasone, diltiazem, efavirenz, erythromycin, etravirine, flecainide, fluconazole, fosamprenavir, gemfibrozil, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, modafinil, nafcillin, nelfinavir, nevirapine, oxcarbazepine, phenobarbital, phenytoin, posaconazole, propafenone, rifabutin, rifampin, rifapentine, ritonavir, saquinavir, St. John’s wort, telithromycin, thioridazine, verapamil, voriconazole |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Human Data Suggest Potential Toxicity |
| 附帶說明 | 懷孕及哺乳建議資料來源為藥品仿單。 |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

